{
    "clinical_study": {
        "@rank": "125955", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date."
            }, 
            {
                "arm_group_label": "Progesterone", 
                "arm_group_type": "Experimental", 
                "description": "The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date."
            }
        ], 
        "brief_summary": {
            "textblock": "Data suggest that progesterone may improve smoking cessation outcomes perhaps by reducing\n      impulsive behavior.  However, the clinical literature on this topic is lacking. Therefore,\n      in Project I we are proposing a double-blind randomized controlled trial to assess the role\n      of exogenous progesterone on impulsivity and smoking cessation in a sample of males and\n      females who are motivated to quit smoking."
        }, 
        "brief_title": "Sex Differences, Hormones & Smoking Cessation", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Tobacco Cessation", 
        "detailed_description": {
            "textblock": "Subjects will be stratified by sex and then randomly assigned to active progesterone (PRO)\n      or placebo (PBO).\n\n      Telephone screening and visit invitation leads to the consent process and in-person\n      screening including medical-psychiatric evaluation for inclusion/exclusion, then\n      randomization and medication induction, stable medication with medication reduction and\n      final evaluation for secondary outcomes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female between 18 and 40 years old\n\n          -  Self-report regular smoking\n\n          -  Motivated to quit smoking\n\n          -  In stable physical/mental health\n\n          -  Self report of regular menstrual cycles (female only)\n\n          -  English fluency\n\n          -  Understand the study procedures and able to provide informed consent\n\n          -  Ability to participate fully in research elements for the duration of the trial.\n\n        Exclusion Criteria:\n\n          -  Current or recent (< 3 months) breastfeeding (females only)\n\n          -  Current or planned pregnancy within the next three months (females only)\n\n          -  Conditions contraindicated to progesterone treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744574", 
            "org_study_id": "2012NTLS074", 
            "secondary_id": "P50DA033942-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Progesterone", 
                "description": "The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.", 
                "intervention_name": "Progesterone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo", 
                    "Progesterone"
                ], 
                "description": "Subjects will receive weekly smoking cessation behavioral counseling.", 
                "intervention_name": "Smoking Cessation Behavioral Counseling", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Progesterone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "contact": {
                "email": "farn0067@umn.edu", 
                "last_name": "Lindsay Farnsworth", 
                "phone": "612-624-4566"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "Delaware Clinical Research Unit, University of Minnesota"
            }, 
            "investigator": {
                "last_name": "Sharon S. Allen, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sex Differences & Progesterone: Association With Impulsivity and Smoking Cessation", 
        "overall_contact": {
            "email": "farn0067@umn.edu", 
            "last_name": "Lindsay Farnsworth", 
            "phone": "612-624-4566"
        }, 
        "overall_contact_backup": {
            "email": "alle0299@umn.edu", 
            "last_name": "Alicia Allen, PhD, MPH", 
            "phone": "612-624-0896"
        }, 
        "overall_official": {
            "affiliation": "Masonic Cancer Center, University of Minnesota", 
            "last_name": "Sharon S. Allen, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Our primary outcome is the binary indicator of relapsed yes/no at the week 4 visit. An unadjusted assessment of the treatment effect will come from a logistic regression of this binary outcome on randomized treatment assignment, separately by sex. All persons randomized and with a measured primary outcome at the week 4 visit will be included in this analysis, regardless of whether or not they ever took any of their assigned treatment (intent-to-treat analysis).", 
            "measure": "Comparison of Subjects Who Relapsed - Male and Female", 
            "safety_issue": "No", 
            "time_frame": "Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744574"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Our secondary outcomes include the binary indicator of relapsed yes/no at the week 12 visit and days to relapse.", 
                "measure": "Comparison of Days to Relapse - All Subjects", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Through Day 84"
            }, 
            {
                "description": "We will pool the male and female data and test for an interaction between sex and treatment assignment in an adjusted Cox regression for the days to relapse outcomes.", 
                "measure": "Comparison of Days to Relapse - Males and Females", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 84"
            }, 
            {
                "description": "Impulsivity Measures (Secondary Outcome): Subjects will complete three self-report measures.\nBehavioral Inhibition/Activation scales (BIS/BAS): These short 20 items forms commonly used scales to study externalizing tendencies.\nBarratt Impulsiveness Scale (BIS): This item contains 30 item self-report measure self-control.\nBrief Self Control Scale (BSCS): This item consists of 13 questions rated on a 4-point scale from \"very true\" to \"very false\" on items reflecting the ability to control problematic behaviors.", 
                "measure": "Comparison of Impulsivity Between Males and Females", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 84"
            }, 
            {
                "description": "Impulsivity Measures (Secondary Outcome): Subjects will complete three self-report measures.\nBehavioral Inhibition/Activation scales (BIS/BAS): These short 20 items forms commonly used scales to study externalizing tendencies.\nBarratt Impulsiveness Scale (BIS): This item contains 30 item self-report measure self-control.\nBrief Self Control Scale (BSCS): This item consists of 13 questions rated on a 4-point scale from \"very true\" to \"very false\" on items reflecting the ability to control problematic behaviors.", 
                "measure": "Comparison of Serum Progesterone Levels Influencing Impulsivity", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Through Day 84"
            }
        ], 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}